EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Vitiligo and Skin Cancer Risk: A Systematic Review and Meta‐Analysis With Subtype and Phototherapy Stratification

Simonetta I. Gaumond, Luis F. Andrade, Peyton V. Warp, Isabella Kamholtz, Sophie Shrestha, Hannah Metheny, Alireza Abdshah, Paolo Romanelli, Joaquin J. Jimenez

JEADV Clinical Practice · 17.08.2026

DOI: 10.1002/jvc2.70418 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift JEADV Clinical Practice, online erschienen am 17.08.2026. Verfasst von Simonetta I. Gaumond und 8 weiteren Autor:innen. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Vitiligo is an autoimmune disorder characterized by CD8+ T cell‐mediated melanocyte destruction and a pro‐inflammatory immune milieu. Despite frequent use of ultraviolet‐based phototherapy, emerging evidence suggests that vitiligo may paradoxically confer a reduced risk of skin cancer. Clarifying this association may provide insight into tumor immune surveillance and inform risk assessment in patients with vitiligo.

Objectives

To evaluate the association between vitiligo and the risk of melanoma and non‐melanoma skin cancers (NMSC), and to assess the potential impact of phototherapy exposure on skin cancer risk.

Methods

A PRISMA‐compliant systematic review and meta‐analysis searched PubMed, Scopus, Embase, and ClinicalTrials.gov through January 2026 for studies comparing skin cancer incidence in patients with vitiligo versus controls. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using Hartung‐Knapp random‐effects models, with assessment of heterogeneity and publication bias.

Results

Fourteen studies were included (454,307 vitiligo patients; 3,583,147 controls), of which nine were eligible for meta‐analysis. Vitiligo was associated with lower odds of melanoma (OR 0.43; 95% CI, 0.16–1.13), with consistent inverse associations across sensitivity analyses. A similar inverse trend was observed for NMSC overall (OR 0.29; 95% CI, 0.06–1.49). Squamous cell carcinoma risk was significantly reduced (OR 0.76; 95% CI 0.57–0.99; p = 0.045), while basal cell carcinoma showed a non‐significant inverse association (OR 0.54; 95% CI, 0.26–1.11). Phototherapy exposure was associated with higher point estimates for melanoma (OR 1.87; 95% CI 0.53–6.54) and NMSC (OR 1.46; 95% CI, 0.37–5.69), although neither association reached statistical significance. Funnel plots and Egger's testing did not detect publication bias.

Conclusions

Vitiligo was associated with lower odds of melanoma and NMSC, with a statistically significant reduction for squamous cell carcinoma. Phototherapy exposure showed higher but non‐significant point estimates. These findings provide a benchmark for baseline cancer risk in vitiligo and may inform safety monitoring of phototherapy and emerging immunomodulatory therapies. PROSPERO number: CRD42024619708.

Zitieren

APA

Gaumond, S. I., Andrade, L. F., Warp, P. V., Kamholtz, I., Shrestha, S., Metheny, H., Abdshah, A., Romanelli, P., & Jimenez, J. J. (2026). Vitiligo and Skin Cancer Risk: A Systematic Review and Meta‐Analysis With Subtype and Phototherapy Stratification. JEADV Clinical Practice. https://doi.org/10.1002/jvc2.70418

Vancouver

Gaumond SI, Andrade LF, Warp PV, Kamholtz I, Shrestha S, Metheny H, et al. Vitiligo and Skin Cancer Risk: A Systematic Review and Meta‐Analysis With Subtype and Phototherapy Stratification. JEADV Clinical Practice. 2026. doi:10.1002/jvc2.70418

BibTeX
@article{Gaumond2026,
  author = {Gaumond, Simonetta I. and Andrade, Luis F. and Warp, Peyton V. and Kamholtz, Isabella and Shrestha, Sophie and Metheny, Hannah and Abdshah, Alireza and Romanelli, Paolo and Jimenez, Joaquin J.},
  title = {Vitiligo and Skin Cancer Risk: A Systematic Review and Meta‐Analysis With Subtype and Phototherapy Stratification},
  journal = {JEADV Clinical Practice},
  year = {2026},
  doi = {10.1002/jvc2.70418}
}
Kostenlos starten →